AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32838353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 86
Study 32838353 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 86
Study 32838353 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiviral medication)
Number of subjects: 86
Study 36175831 — intervention group
Group type: EXPERIMENTAL
Intervention: AUD$10 unconditional incentive
Number of subjects: 238
Study 36175831 — intervention group
Group type: EXPERIMENTAL
Intervention: AUD$20 unconditional incentive
Number of subjects: 238
Study 36175831 — intervention group
Group type: COMPARATOR
Intervention: Comparison of response rates between AUD$10 and AUD$20 groups
Number of subjects: 238
Study 34127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using G-EO system (30 min traditional therapy + 20 min robotic treatment)
Number of subjects: 152
Study 34127032 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation program (50 min traditional therapy)
Number of subjects: 152
Study 34127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using G-EO system
Number of subjects: 152
Study 34127032 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation program
Number of subjects: 152
Study 32805198 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for systolic blood pressure (GRSSBP)
Number of subjects: 0
Study 32805198 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for diastolic blood pressure (GRSDBP)
Number of subjects: 0
Study 32805198 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for mean arterial pressure (GRSMAP)
Number of subjects: 0
Study 32805198 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for pulse pressure (GRSPP)
Number of subjects: 0
Study 32805198 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for hypertension (GRSHTN)
Number of subjects: 0
Study 32805198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined genetic risk scores (GRScomb)
Number of subjects: 0
Study 32805198 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 0
Study 35337743 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.5, 1, 2, 5, and 10 μg/kg/min)
Number of subjects: 58
Study 35337743 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 58
Study 35466156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/day × 4 days)
Number of subjects: 420
Study 35466156 — intervention group
Group type: COMPARATOR
Intervention: No pitavastatin (Control group)
Number of subjects: 420
Study 34986478 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Number of subjects: 0
Study 34986478 — intervention group
Group type: COMPARATOR
Intervention: Aromatherapy
Number of subjects: 0
Study 33957724 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-ketamine (Group K; n = 50)
Number of subjects: 100
Study 33957724 — intervention group
Group type: COMPARATOR
Intervention: propofol-fentanyl (Group F; n = 50)
Number of subjects: 100
Study 32568935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay patient navigation intervention (5 home visits over 3 months)
Number of subjects: 112
Study 32568935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay patient navigation intervention
Number of subjects: 112
Study 36005883 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 4 g/d
Number of subjects: 61
Study 36005883 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 1 g/d
Number of subjects: 61
Study 36005883 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 2 g/d
Number of subjects: 61
Study 36005883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32145103 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular fitness
Number of subjects: 201
Study 32145103 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed-agility
Number of subjects: 201
Study 32145103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 201
Study 32145103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall fitness score
Number of subjects: 201
Study 33392769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive doxycycline prophylaxis for anti-EGFR-related skin toxicity
Number of subjects: 226
Study 32070283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (10 l/min)
Number of subjects: 160
Study 32070283 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 160
Study 33874750 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 33874750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 33874750 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2i (pooled from 4 CVOTs)
Number of subjects: 4401
Study 32312112 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE)
Number of subjects: 1672
Study 35109841 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (20 mg/kg/day) plus Clindamycin (20 mg/kg/day) for 3 days
Number of subjects: 384
Study 35109841 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (artemether 20 mg, lumefantrine 120 mg) for 3 days
Number of subjects: 384
Study 33736706 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 88
Study 33736706 — intervention group
Group type: COMPARATOR
Intervention: Balance and tone training (active control)
Number of subjects: 88
Study 35410590 — intervention group
Group type: EXPERIMENTAL
Intervention: PartoMa intervention (co-created clinical practice guidelines and low-dose, high-frequency training)
Number of subjects: 5
Study 35410590 — intervention group
Group type: EXPERIMENTAL
Intervention: PartoMa intervention
Number of subjects: 5
Study 32316790 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle human touch during endotracheal suctioning
Number of subjects: 34
Study 32316790 — intervention group
Group type: COMPARATOR
Intervention: No intervention (suctioning without gentle human touch)
Number of subjects: 34
Study 33431052 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose saccharin supplementation (administered in capsules twice daily for 2 weeks)
Number of subjects: 0
Study 33431052 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose saccharin supplementation
Number of subjects: 0
Study 33431052 — intervention group
Group type: COMPARATOR
Intervention: T1R2-KO mice (compared to WT)
Number of subjects: 0
Study 33431052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33431052 — intervention group
Group type: COMPARATOR
Intervention: Lactisole (STR inhibitor)
Number of subjects: 0
Study 33431052 — intervention group
Group type: COMPARATOR
Intervention: Saccharin with lactisole
Number of subjects: 0
Study 32004499 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-IV resistant starches (RS4s), specifically crystalline and phosphate cross-linked starch structures, administered at a dose of 35 g/day.
Number of subjects: 0
Study 32004499 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-IV resistant starches (RS4s) at a dose of 35 g/day.
Number of subjects: 0
Study 35991892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydromorphone PCA (0.05 mg/h with 0.2 mg on-demand)
Number of subjects: 77
Study 35991892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydromorphone PCA
Number of subjects: 77
Study 35991892 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine (50 mg as required)
Number of subjects: 77
Study 33422288 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive communication behaviour during medical handover
Number of subjects: 64
Study 33422288 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardised handover without positive communication)
Number of subjects: 64
Study 33769373 — intervention group
Group type: EXPERIMENTAL
Intervention: Early transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 0
Study 33769373 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive therapy (octreotide)
Number of subjects: 0
Study 33769373 — intervention group
Group type: COMPARATOR
Intervention: Thromboelastography-guided approach
Number of subjects: 0
Study 33769373 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding metallic stents
Number of subjects: 0
Study 33769373 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-based transfusion strategies
Number of subjects: 0
Study 33769373 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 34362816 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 25
Study 34362816 — intervention group
Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 25
Study 36231767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 80
Study 36231767 — intervention group
Group type: COMPARATOR
Intervention: Ischemic Compression (IC)
Number of subjects: 80
Study 33704046 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 0
Study 33704046 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32356470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB)
Number of subjects: 80
Study 32356470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no QLB)
Number of subjects: 80
Study 35392478 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat mini program-based intervention
Number of subjects: 158
Study 35392478 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 158
Study 33971625 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature-based nomogram
Number of subjects: 105
Study 33971625 — intervention group
Group type: COMPARATOR
Intervention: Traditional morphological features
Number of subjects: 105
Study 33971625 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomics signature and traditional morphological features
Number of subjects: 105
Study 36033731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram to predict ICU prolonged LOS
Number of subjects: 14483
Study 32454161 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (60 mg)
Number of subjects: 12
Study 32454161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34533832 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metformin gel plus platelet-rich fibrin (PRF)
Number of subjects: 21
Study 34533832 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich fibrin (PRF) alone
Number of subjects: 21
Study 33543637 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review with follow-up
Number of subjects: 291
Study 616768438 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 20
Study 616768438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34407385 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized CA-guided CPP targets
Number of subjects: 60
Study 34407385 — intervention group
Group type: COMPARATOR
Intervention: Brain Trauma Foundation (BTF) guideline CPP target range
Number of subjects: 60
Study 36422517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention (8 weekly online classes)
Number of subjects: 79
Study 36422517 — intervention group
Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 79
Study 36422517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention
Number of subjects: 79
Study 33407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy
Number of subjects: 81
Study 33407868 — intervention group
Group type: COMPARATOR
Intervention: Palliative treatment
Number of subjects: 81
Study 32062052 — intervention group
Group type: EXPERIMENTAL
Intervention: Welcome-IdA case conference model
Number of subjects: 465
Study 32062052 — intervention group
Group type: EXPERIMENTAL
Intervention: Welcome-Neo case conference model
Number of subjects: 465
Study 32062052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 465
Study 32062052 — intervention group
Group type: EXPERIMENTAL
Intervention: IdA cohort staff
Number of subjects: 465
Study 33297841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (15g) + glycerol (9.45g)
Number of subjects: 23
Study 33297841 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose (15g)
Number of subjects: 23
Study 32768361 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02%/latanoprost 0.005% FDC
Number of subjects: 718
Study 32768361 — intervention group
Group type: COMPARATOR
Intervention: Netarsudil 0.02% only
Number of subjects: 718
Study 32768361 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% only
Number of subjects: 718
Study 32726003 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules
Number of subjects: 22065
Study 32726003 — intervention group
Group type: COMPARATOR
Intervention: Health guidance only (non-intervention group)
Number of subjects: 22065
Study 34761713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 2375
Study 34761713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2375
Study 32999317 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-stiffness prosthetic foot set to randomized stiffness
Number of subjects: 7
Study 32999317 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication between amputee subjects and one prosthetist subject to arrive at a mutually preferred stiffness
Number of subjects: 7
Study 35385504 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular warning label (TL)
Number of subjects: 1384
Study 35385504 — intervention group
Group type: COMPARATOR
Intervention: Rectangular 'high in' label with magnifying glass (ML)
Number of subjects: 1384
Study 33370633 — intervention group
Group type: EXPERIMENTAL
Intervention: PNS + ASA
Number of subjects: 42
Study 33370633 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 42
Study 34487395 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 143
Study 34487395 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX)
Number of subjects: 143
Study 32445429 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 130
Study 32445429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 36494114 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash and dentifrice containing antimicrobial phthalocyanine derivative (APD)
Number of subjects: 134
Study 36494114 — intervention group
Group type: COMPARATOR
Intervention: Non-APD (control)
Number of subjects: 134
Study 33581920 — intervention group
Group type: EXPERIMENTAL
Intervention: QVLP (30 μg HA/strain) from three sequential lots
Number of subjects: 1200
Study 33109654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active referral combined with a financial incentive (HK$300)
Number of subjects: 1134
Study 36044391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 115
Study 36044391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 34898447 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC combined with usual care
Number of subjects: 222
Study 34898447 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study 34461886 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular continuous suture with Monocryl®
Number of subjects: 63
Study 34461886 — intervention group
Group type: COMPARATOR
Intervention: Traditional suture with MonoNylon®
Number of subjects: 63
Study 34461886 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture with Stratafix®
Number of subjects: 63
Study 33372300 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic rhinosinusitis (CRS) patients with prolonged viral shedding
Number of subjects: 54
Study 33372300 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex-matched without prolonged viral shedding)
Number of subjects: 54
Study 33372300 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids usage in CRS patients
Number of subjects: 54
Study 33372300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy in CRS patients
Number of subjects: 54
Study 32384719 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Number of subjects: 27
Study 32384719 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 27
Study 34058873 — intervention group
Group type: EXPERIMENTAL
Intervention: Early irrigation and debridement (I&D) within six hours of injury
Number of subjects: 2286
Study 34058873 — intervention group
Group type: COMPARATOR
Intervention: Late irrigation and debridement (I&D) beyond six hours of injury
Number of subjects: 2286
Study 33258553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 11 mg XR daily
Number of subjects: 10
Study 36427600 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52‐mg intrauterine device
Number of subjects: 655
Study 36427600 — intervention group
Group type: COMPARATOR
Intervention: Copper T380A intrauterine device
Number of subjects: 655
Study 32022640 — intervention group
Group type: EXPERIMENTAL
Intervention: Light regulation with light-emitting goggles in the morning and amber-lens glasses in the evening
Number of subjects: 26
Study 32022640 — intervention group
Group type: COMPARATOR
Intervention: No light regulation
Number of subjects: 26
Study 32065672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray
Number of subjects: 48
Study 32065672 — intervention group
Group type: COMPARATOR
Intervention: Diazepam rectal gel
Number of subjects: 48
Study 32065672 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 48
Study 35222658 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (intervention group)
Number of subjects: 52
Study 35222658 — intervention group
Group type: COMPARATOR
Intervention: No magnesium supplementation (control group)
Number of subjects: 52
Study 33207040 — intervention group
Group type: COMPARATOR
Intervention: Transient injury group (recovery ≤2 days)
Number of subjects: 2693
Study 33207040 — intervention group
Group type: COMPARATOR
Intervention: Persistent injury group (recovery 3-7 days)
Number of subjects: 2693
Study 33207040 — intervention group
Group type: COMPARATOR
Intervention: Acute kidney disease group (recovery ≥8 days)
Number of subjects: 2693
Study 33207040 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no AKI)
Number of subjects: 2693
Study 35909263 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 60
Study 35909263 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 60
Study 35909263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mg corn starch)
Number of subjects: 60
Study 33580745 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-OA (60/20 mg orlistat/mg acarbose)
Number of subjects: 67
Study 33580745 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-OA (90/30 mg orlistat/mg acarbose)
Number of subjects: 67
Study 33580745 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-OA (120/40 mg orlistat/mg acarbose)
Number of subjects: 67
Study 33580745 — intervention group
Group type: COMPARATOR
Intervention: Conventional orlistat (Xenical, 120 mg)
Number of subjects: 67
Study 32193166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitspiration captions
Number of subjects: 109
Study 32193166 — intervention group
Group type: EXPERIMENTAL
Intervention: Body positive captions
Number of subjects: 109
Study 32193166 — intervention group
Group type: COMPARATOR
Intervention: Neutral captions
Number of subjects: 109
Study 35576279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement (LNS) (535 kcal)
Number of subjects: 34
Study 35576279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (92 kcal)
Number of subjects: 34
Study 33421559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (2 g)
Number of subjects: 60
Study 33421559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35578688 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 70
Study 35578688 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 34810365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single implant mandibular overdentures (1IMO)
Number of subjects: 52
Study 34810365 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implant mandibular overdentures (2IMO)
Number of subjects: 52
Study 34810365 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 1IMO and 2IMO
Number of subjects: 52
Study 33860389 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 101
Study 33860389 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 101
Study 32239968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-derived fortifier (CMDF)
Number of subjects: 114
Study 32239968 — intervention group
Group type: COMPARATOR
Intervention: HM-derived fortifier (HMDF)
Number of subjects: 114
Study 35971135 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-GAP + Texting
Number of subjects: 17
Study 35971135 — intervention group
Group type: COMPARATOR
Intervention: Texting only
Number of subjects: 17
Study 33543897 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 5 units intravenous alone
Number of subjects: 102
Study 33543897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus ergonovine 0.25 mg intravenous
Number of subjects: 102
Study 33543897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus carboprost 0.25 mg intramuscular
Number of subjects: 102
Study 34908146 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medical Group Visits (IMGV)
Number of subjects: 0
Study 32738795 — intervention group
Group type: EXPERIMENTAL
Intervention: Expandable screws
Number of subjects: 40